logo

Asia - Pacific Human Insulin Market Size (2024 - 2029)

The Asia-Pacific human insulin market is projected to experience growth over the forecast period, driven by an increasing prevalence of diabetes, particularly Type 2, in the region. This growth is influenced by factors such as an aging population, sedentary lifestyles, and the rising incidence of obesity, which contribute to elevated sugar levels. The market's expansion is supported by the presence of key anti-diabetic medicine manufacturers in the region. However, the high cost of pharmaceuticals remains a significant barrier, limiting access to insulin for many patients who require it.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Hyperglycemics Research APAC Insulin Industry Market Size

Market Size of Asia - Pacific Human Insulin Industry

Asia - Pacific Human Insulin Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Market Size (2024) USD 7.48 Billion
Market Size (2029) USD 8.48 Billion
CAGR (2024 - 2029) 2.54 %
Market Concentration High

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Asia-Pacific Human Insulin Market Analysis

The Asia - Pacific Human Insulin Market size is estimated at USD 7.48 billion in 2024, and is expected to reach USD 8.48 billion by 2029, growing at a CAGR of 2.54% during the forecast period (2024-2029).

During the COVID-19 crisis, the Asia-Pacific diabetes market saw a gradual growth in demand for diabetic medications. According to a 2021 BeatO research on 800 participants, patients with COVID-19 and pre-existing diabetes suffered blood glucose level changes, resulting in a significant need for advanced diabetic medicines. To mitigate the disastrous impact of COVID-19, Novo Nordisk established a new social responsibility plan to combat diabetes, intending to provide patients in every nation with access to affordable diabetic care.

Diabetes patients, particularly those with Type 2 diabetes, have increased rapidly in Asian nations during the last few decades. Developing nations account for more than 70% of the worldwide diabetes population. The Asia-Pacific region is expected to develop significantly due to an aging population and rising diabetes prevalence, mostly due to increased stress, sedentary lifestyles, smoking, and excessive alcohol intake, which raises the body's sugar levels. Furthermore, the region's production base of key anti-diabetic medicine businesses aided market expansion. However, one of the primary constraining factors for the industry is the rising cost of pharmaceuticals.

The genetic factor is one of the primary reasons for the rapid spread of the disease. Sedentary lifestyles and obesity are the other factors responsible for the high prevalence of the disease. Although insulin has been used for treating diabetes for over 90 years, more than half of those who need insulin today still cannot afford and access it due to the high cost of the product.

Asia-Pacific Human Insulin Industry Segmentation

Regular insulin is a kind of medical short-acting insulin, sometimes referred to as neutral and soluble insulin. Type 1 diabetes, Type 2 diabetes, gestational diabetes, and diabetic complications such as diabetic ketoacidosis and hyperosmolar hyperglycemic states are all treated with it. Asia-Pacific Human Insulin Market is segmented into Product Type and by Asia-Pacific. The market provides the value (in USD) and Volume (in ml) for the above-mentioned segments.

Drug
Insulin
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Abasaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
FIASP (Insulin Aspart)
Admelog (Insulin Lispro)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humilin
Insuman
Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
South Korea
Thailand
Vietnam
Rest of Asia-Pacific
Need A Different Region Or Segment?
Customize Now

Asia - Pacific Human Insulin Market Size Summary

The Asia-Pacific human insulin market is poised for steady growth over the forecast period, driven by an increasing prevalence of diabetes, particularly Type 2, across the region. This rise is attributed to factors such as an aging population, sedentary lifestyles, and genetic predispositions, which have contributed to a significant portion of the global diabetes population residing in developing Asian countries. The market's expansion is further supported by the region's robust production base of key anti-diabetic medicine companies. However, the high cost of pharmaceuticals remains a significant challenge, limiting access to insulin for many patients who require it. Despite these challenges, the market is expected to benefit from initiatives like Novo Nordisk's social responsibility plan, which aims to enhance access to affordable diabetic care across Asia-Pacific nations.

China and India are at the forefront of the diabetes epidemic in the region, with China anticipated to maintain its dominant market position due to its large patient pool and favorable regulatory environment for insulin biosimilars. The market is characterized by intense competition, with global players facing challenges from local companies offering biosimilar insulin at lower prices. The consolidation of the market is evident through strategic partnerships and acquisitions, such as Sandoz's collaboration with Gan & Lee. These developments, alongside the increasing availability of generic drug manufacturers, are expected to drive the market's growth. The Asia-Pacific region's dominance in the global diabetes market underscores the critical need for effective diabetes management solutions, including insulin, to address the rising health burden.

Explore More

Asia - Pacific Human Insulin Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Drivers

    3. 1.3 Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drug

      1. 2.1.1 Insulin

        1. 2.1.1.1 Basal or Long Acting Insulins

          1. 2.1.1.1.1 Lantus (Insulin Glargine)

          2. 2.1.1.1.2 Levemir (Insulin Detemir)

          3. 2.1.1.1.3 Toujeo (Insulin Glargine)

          4. 2.1.1.1.4 Tresiba (Insulin Degludec)

          5. 2.1.1.1.5 Abasaglar (Insulin Glargine)

        2. 2.1.1.2 Bolus or Fast Acting Insulins

          1. 2.1.1.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 2.1.1.2.2 Humalog (Insulin Lispro)

          3. 2.1.1.2.3 Apidra (Insulin Glulisine)

          4. 2.1.1.2.4 FIASP (Insulin Aspart)

          5. 2.1.1.2.5 Admelog (Insulin Lispro)

        3. 2.1.1.3 Traditional Human Insulins

          1. 2.1.1.3.1 Novolin/Actrapid/Insulatard

          2. 2.1.1.3.2 Humilin

          3. 2.1.1.3.3 Insuman

        4. 2.1.1.4 Insulin Combinations

          1. 2.1.1.4.1 NovoMix (Biphasic Insulin Aspart)

          2. 2.1.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. 2.1.1.4.3 Xultophy (Insulin Degludec and Liraglutide)

          4. 2.1.1.4.4 Soliqua/Suliqua (Insulin Glargine and Lixisenatide)

        5. 2.1.1.5 Biosimilar Insulins

          1. 2.1.1.5.1 Insulin Glargine Biosimilars

          2. 2.1.1.5.2 Human Insulin Biosimilars

    2. 2.2 Geography

      1. 2.2.1 Australia

      2. 2.2.2 China

      3. 2.2.3 India

      4. 2.2.4 Indonesia

      5. 2.2.5 Japan

      6. 2.2.6 Malaysia

      7. 2.2.7 Philippines

      8. 2.2.8 South Korea

      9. 2.2.9 Thailand

      10. 2.2.10 Vietnam

      11. 2.2.11 Rest of Asia-Pacific

Asia - Pacific Human Insulin Market Size FAQs

The Asia - Pacific Human Insulin Market size is expected to reach USD 7.48 billion in 2024 and grow at a CAGR of 2.54% to reach USD 8.48 billion by 2029.

In 2024, the Asia - Pacific Human Insulin Market size is expected to reach USD 7.48 billion.

Asia-Pacific Human Insulin Market Report Snapshots

Asia-Pacific Human Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)